Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

WHICH CAN SAVE YOU FROM A CYSTOSCOPY IF IT SHOWS THAT YOUR RISK OF BLADDER CANCER IS VERY LOW OR VERY HIGH, AND IT PUSHES YOU MORE TOWARDS MORE SCREENING AND MORE SCOPES IN TERMS OF TREATMENT ...

Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure ...

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

“Bladder cancer is most commonly diagnosed by a cystoscopy, a procedure that places a scope [camera] in the bladder and up the ureteral tract (the tube connecting the kidneys to the bladder ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...